Revolution Medicines Inc reports results for the quarter ended in January 1 - Earnings Summary

• Revolution Medicines Inc RVMD.OQ reported a quarterly adjusted loss of 94 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -99 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 89 cents per share. Wall Street expected results to range from -97 cents to -77 cents per share.

• Reported revenue was zero​; analysts expected $321.43 thousand.

• Revolution Medicines Inc's reported EPS for the quarter was a loss of 94 cents​.

• The company reported a quarterly loss of $156.29 million.

• Revolution Medicines Inc shares had risen by 31.0% this quarter and gained 107.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Revolution Medicines Inc is $70.00

This summary was machine generated from LSEG data November 7 at 03:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)